| Psoriasis vulgaris
Amjevita vs Otezla
Side-by-side clinical, coverage, and cost comparison for psoriasis vulgaris.Deep comparison between: Amjevita vs Otezla with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsOtezla has a higher rate of injection site reactions vs Amjevita based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Otezla but not Amjevita, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Amjevita
Otezla
At A Glance
SC injection
Every other week
TNF-alpha antagonist
Oral
Once or twice daily
PDE4 inhibitor
Indications
- Rheumatoid Arthritis
- Juvenile arthritis
- Arthritis, Psoriatic
- Ankylosing spondylitis
- Crohn Disease
- Ulcerative Colitis
- Psoriasis vulgaris
- Hidradenitis Suppurativa
- Uveitis
- Arthritis, Psoriatic
- Psoriasis vulgaris
- Behcet Syndrome
Dosing
Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis Adults: 40 mg SC every other week; some RA patients not receiving MTX may benefit from 40 mg every week or 80 mg every other week.
Juvenile arthritis, Uveitis (pediatric, >=2 years) Weight-based SC every other week: 10 mg (10 to <15 kg), 20 mg (15 to <30 kg), 40 mg (>=30 kg).
Crohn Disease (adults) 160 mg SC on Day 1, 80 mg on Day 15, then 40 mg every other week starting Day 29.
Crohn Disease (pediatric, >=6 years) Weight-based: 80 mg Day 1 / 40 mg Day 15 / 20 mg every other week (17 to <40 kg); 160 mg Day 1 / 80 mg Day 15 / 40 mg every other week (>=40 kg).
Ulcerative Colitis Adults: 160 mg SC on Day 1, 80 mg on Day 15, then 40 mg every other week starting Day 29; discontinue if no clinical remission by Day 57.
Psoriasis vulgaris, Uveitis (adults) 80 mg SC initial dose, then 40 mg every other week starting one week after the initial dose.
Hidradenitis Suppurativa (adults) 160 mg SC on Day 1, 80 mg on Day 15, then 40 mg every week or 80 mg every other week starting Day 29.
Hidradenitis Suppurativa (adolescents >=12 years, >=30 kg) Weight-based: 80 mg Day 1 / 40 mg every other week from Day 8 (30 to <60 kg); 160 mg Day 1 / 80 mg Day 15 / 40 mg weekly or 80 mg every other week from Day 29 (>=60 kg).
Arthritis, Psoriatic, Psoriasis vulgaris, Behcet Syndrome Adults: OTEZLA 30 mg twice daily or OTEZLA XR 75 mg once daily orally after 5-day titration starting at 10 mg; reduce to 30 mg once daily in severe renal impairment (OTEZLA XR not recommended in severe renal impairment).
Arthritis, Psoriatic, Psoriasis vulgaris (pediatric >=6 years) Weighing >=50 kg: OTEZLA 30 mg twice daily or OTEZLA XR 75 mg once daily orally after weight-based titration; weighing 20 to <50 kg: OTEZLA 20 mg twice daily orally; reduce to once daily dosing in severe renal impairment.
Contraindications
—
- Known hypersensitivity to apremilast or to any of the excipients in the formulation
Adverse Reactions
Most common (>=5%) Injection site reactions, upper respiratory infection, sinusitis, headache, rash, nausea, urinary tract infection, flu syndrome, abdominal pain, back pain, hypertension.
Serious Serious infections (pneumonia, septic arthritis, erysipelas, cellulitis, diverticulitis, pyelonephritis), tuberculosis, opportunistic infections, malignancies, hypersensitivity reactions, hepatitis B virus reactivation, neurologic reactions, hematological reactions, heart failure, autoimmunity.
Postmarketing Diverticulitis, large bowel perforations, pancreatitis, pyrexia, liver failure, autoimmune hepatitis, sarcoidosis, Merkel Cell Carcinoma, demyelinating disorders, cerebrovascular accident, interstitial lung disease, pulmonary embolism, Stevens Johnson Syndrome, cutaneous vasculitis, erythema multiforme, new or worsening psoriasis, alopecia, systemic vasculitis, deep vein thrombosis.
Most common (>=2%) Diarrhea, nausea, headache, upper respiratory tract infection, vomiting, abdominal pain upper, nasopharyngitis
Serious Hypersensitivity, depression, weight decrease, severe worsening of psoriasis (rebound)
Pharmacology
Adalimumab-atto is a recombinant human IgG1 monoclonal antibody that binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors, inhibiting TNF-mediated inflammatory and immune responses; it also lyses surface TNF-expressing cells in vitro in the presence of complement and modulates downstream biological responses including adhesion molecule expression (ELAM-1, VCAM-1, ICAM-1).
Apremilast is an oral small molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP); PDE4 inhibition increases intracellular cAMP levels and reduces pro-inflammatory cytokines including IL-17, IL-22, and TNF-alpha in blood and skin.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Amjevita
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Otezla
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (12/12) · Qty limit (9/12)
UnitedHealthcare
Amjevita
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (6/8)
Otezla
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (2/8) · Qty limit (8/8)
Humana
Amjevita
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Otezla
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Amjevita.
Cost estimate not availableAmgen Safety Net Foundation: Otezla
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AmjevitaView full Amjevita profile
OtezlaView full Otezla profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.